An observational study in Obesity (BMI Equal to or >30), sponsored by Technical University of Munich. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Technical University of Munich · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Obesity by Technical University of Munich — 4 open to participants now, 4 under way, none of them phase 3. Obesity · Technical University of Munich.
Among the 10 studies in Obesity by Technical University of Munich, this one is one of 4 that started in 2026, is one of 4 observational ones, and was the 8th registered.
11,529 studies on the registry are indexed under Obesity; 2,035 are open to participants now.
Browse Obesity studies →4 of the 10 studies in Obesity by Technical University of Munich are open now, in 1 country. Recruiting first, the newest first:
Technical University of Munich · Sites in Germany
Ages 18–60
Technical University of Munich
Ages 18–60
Technical University of Munich · Sites in Germany
Ages 18–60
By country, each count listing its studies:
Of the 1,336 Obesity studies recruiting now, 377 (28%) set no upper age limit and 856 (64%) stop at 75 or younger; 166 take children under 18; 488 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2026.
This study's planned enrollment of 150 is above the median of 115 across 2,157 observational studies indexed under Obesity.
Median enrollment 240 across the 6 interventional studies, 150 across the 4 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Technical University of Munich is the lead sponsor of 322 studies on the registry; 60 are open to participants now.
4 of the studies in Obesity by Technical University of Munich that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07931196Technical University of MunichMolecular and Microbiome Changes During Tirzepatide Treatment and Resistance Training in Obesity | 2027-06-30 |
| NCT07931235Technical University of MunichBreath Acetone During Tirzepatide Treatment and Resistance Training in Adults With Obesity | 2027-07-31 |
| NCT07929571Technical University of MunichFunctional, Cognitive, and Behavioral Correlates of Resistance Training During Tirzepatide-Induced Weight Loss | 2027-07-31 |
| NCT07777575Technical University of MunichResistance Training to Prevent Muscle Loss During Treatment With Tirzepatide | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 10 studies in Obesity by Technical University of Munich, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is an ancillary study to the RESIST trial, in which adults with obesity receive the weight-loss medication tirzepatide and are randomly assigned to a structured resistance training program or to usual care for 24 weeks. RESIST-EXPLORE investigates which molecular, metabolic, inflammatory, immune-cell and microbiome-related changes occur during this treatment, and how they relate to changes in body weight, body composition and muscle-related outcomes measured in RESIST. Blood samples are collected at the start (Week 0) and at the end (Week 24) of treatment; stool samples and tongue and nasal swabs are collected at Week 0, Week 4 and Week 24.
RESIST-EXPLORE is a prospective, observational, monocentric ancillary study to the RESIST trial conducted at the TUM Klinikum, Munich, Germany, in collaboration with Helmholtz Munich. Active participation in the RESIST trial (protocol code RESIST-26-HAL-0150-I; EU CT number 2026-526200-69-00) is a prerequisite for enrolment. RESIST is a randomized, controlled, open-label Phase IV trial evaluating a structured resistance training program versus usual care in 150 adults with obesity treated with tirzepatide (Mounjaro®) over 24 weeks.
RESIST-EXPLORE aims to characterize treatment-associated changes in molecular, metabolic, inflammatory, immune-cell, and microbiome profiles, and to examine their associations with changes in body weight, body composition, and muscle-related outcomes. All analyses are exploratory.
RESIST-EXPLORE involves no investigational medicinal product, no intervention and no randomization. Assignment to resistance training or usual care occurs exclusively within the RESIST trial. In RESIST-EXPLORE, biosamples are collected at RESIST visits: blood (plasma, serum, circulating immune cells) at baseline (V1, Week 0) and end of treatment (V7, Week 24); stool samples (self-collected at home) and tongue and nasal swabs at V1, V2 (Week 4) and V7. Short questionnaires on factors relevant to microbiome analyses (e.g., antibiotic use, diet, stool consistency, oral and nasal health) are completed at each microbiome sampling time point.
Planned analyses include proteomic and other biomarker analyses of plasma and serum; immune cell profiling by flow cytometry, functional immune assays and transcriptomic analyses including single-cell RNA sequencing; and characterization of the intestinal, oral and nasal microbiome by 16S rRNA sequencing and shotgun metagenomics, including microbial metabolites such as short-chain fatty acids and volatile organic compounds. Biosample-derived data are linked with clinical data from the RESIST trial.
Participants of the RESIST trial at the TUM Klinikum, Munich: adults aged 18-60 years with obesity (BMI ≥ 30 kg/m²) without manifest type 2 diabetes or structural cardiovascular disease, eligible for pharmacological weight-loss therapy and suitable for a structured resistance training program. Sufficient command of German is required
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Key eligibility criteria of the RESIST trial (for context only; full criteria see RESIST protocol RESIST-26-HAL-0150-I):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RESIST participants randomized to the structured resistance training arm of the RESIST trial, receiving tirzepatide and individualized diet and physical activity counselling. Assignment occurs within RESIST, not within this ancillary study.
Behavioral: Structured resistance training · Drug: Tirzepatide
RESIST participants randomized to the usual care arm of the RESIST trial, receiving tirzepatide and individualized diet and physical activity counselling. Assignment occurs within RESIST, not within this ancillary study.
Drug: Tirzepatide
Machine-based structured resistance training over 24 weeks (72 sessions, approx. 3 sessions per week), delivered within the RESIST trial (not part of this ancillary study). Progressive program with an acclimation phase (weeks 1-4) and a target phase (weeks 5-24; 8-12 repetitions at approx. 70-75% 1-RM, with additional eccentric overload from week 9). Sessions are fully supervised during the first 6 weeks whenever feasible, thereafter at least one supervised session after each interim visit; remaining sessions at the trial site or at partner fitness facilities.
Once-weekly subcutaneous injection over 24 weeks, starting at 2.5 mg/week and increased by 2.5 mg every 4 weeks as tolerated up to a maximum of 10 mg/week, in accordance with the SmPC. Administered within the RESIST trial (not part of this ancillary study).
Change in circulating protein biomarker profile (plasma/serum)
Circulating proteins related to inflammation, metabolism and cardiovascular health measured by high-throughput proteomics (e.g., Olink®).
Time frame: Baseline (Week 0) and end of treatment (Week 24)
Change in frequencies of circulating lymphocyte subsets
Frequencies of circulating lymphocyte subsets, including subsets defined by markers of activation, senescence and exhaustion, measured by multiparameter flow cytometry and expressed as percentage of the respective parent population.
Time frame: Baseline (Week 0) and end of treatment (Week 24)
Change in gut microbiome composition and diversity (stool)
Microbial composition and diversity determined by 16S rRNA sequencing and shotgun metagenomics.
Time frame: Baseline (Week 0), Week 4 and end of treatment (Week 24)
Change in oral microbiome composition and diversity (tongue swab)
Microbial composition and diversity determined by 16S rRNA sequencing and shotgun metagenomics.
Time frame: Baseline (Week 0), Week 4 and end of treatment (Week 24)
Change in nasal microbiome composition and diversity (nasal swab)
Microbial composition and diversity determined by 16S rRNA sequencing and shotgun metagenomics.
Time frame: Baseline (Week 0), Week 4 and end of treatment (Week 24)
Change in functional immune responses
T-cell receptor-mediated activation and inflammasome assays, including assays using participant serum.
Time frame: Baseline (Week 0) and end of treatment (Week 24)
Change in immune cell transcriptome
Transcriptomic analyses of isolated immune cells, including single-cell RNA sequencing
Time frame: Baseline (Week 0) and end of treatment (Week 24)
Change in microbial metabolites
Short-chain fatty acids and volatile organic compounds
Time frame: Baseline (Week 0), Week 4 and end of treatment (Week 24)
No study locations are listed for this record.
Plan to share: No — Individual participant data will not be made publicly available due to privacy restrictions. Pseudonymized data and biosamples are shared only with research partners and service providers to the extent required for the analyses defined in the protocol, under appropriate data or material transfer agreements.
Start is estimated for Oct 2026; primary completion for Jun 2027, 8 months later.
Of 792 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 8 months is below that.
Counting every sponsor, half of 837 studies reached it within 39 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Technical University of Munich →